Robin List teams up with Vendis Capital to further develop Sylphar, a promising OTC company

Deurle (Belgium), 15 May 2017 – Vendis Capital, the private equity fund specialized in the consumer brands sector, invests alongside Robin List and his management team in Sylphar, an OTC company poised for growth.

Sylphar, headquartered in Deurle (Belgium), is a fast-growing OTC company with a portfolio of brands in the oral beauty, oral therapy and medicated skincare market segments.

Sylphar focuses on bringing innovative and consumer friendly products to the market. The company offers teeth whitening products under the leading brand iWhite, an innovative range of solutions for specific skin conditions under the Remescar brand, and oral therapeutics under the Herpatch (cold sores and ulcers) and Shur (bad breath) brands.

Started by Robin List in 2008 as a spin-off from a publicly listed dental company and supported by Dutch private equity fund Concordia, Sylphar has experienced a steep growth curve over the last years through continuous product innovation and geographic roll-out. Present in more than 50 countries worldwide, the company focuses on developing and marketing innovative products that are brought to the market through local distribution partners.

Founder and Group CEO Robin List explains: “Thanks to the hard work of the team, we have built a solid track record of success so far, but I’m convinced there is still much to be done. We have indeed the ambition to build a portfolio of a small number of strategic niche brands that will have a leading position in their respective categories and geographies, be it organically or through acquisitions. We believe Vendis is the right partner to help us achieve that goal.”

Concordia Fund Partner Saskia van Walsum adds: “Concordia Fund has been shareholder in Sylphar since the spin-off in 2008 and it was the start of a new story for the company. Robin List and his team have proven since to be able to develop brands and products as well as the company. To build Sylphar internationally almost from scratch and to handle the growing pains was not an easy road to travel. And being fast growing and successful in 10 years time is a great achievement. Sylphar is now ready for a new shareholder and a new chapter – as is Concordia Fund. Concordia Fund is very well rewarded for this almost 10 year pleasant and constructive partnership.  We thank Robin and the dedicated Sylphar team, and wish the team all the best in this new stage of the company.”

Vendis Capital Partner Cedric Olbrechts concludes: “We have been impressed by the way Robin and his team have managed to develop the company and we are convinced this could just be the start of a fantastic new growth story. Sylphar is a solid growing company evolving in a favorable business environment and well positioned on its key products. It is also a great platform for the acquisitions we will actively look for. We look forward to contribute to the future development of the company and to work with Robin and his great team.”